Menstrual Blood Loss and the Durability of Iron Repletion in Endurance Athletes a Critical Review of Athlete Follow-Up, Oral Dosing and Bleeding Treatment
Keywords:
endurance athletes; heavy menstrual bleeding; ferritin; iron treatment; running economy; treatment follow-upAbstract
To assess the duration of biochemical correction after iron treatment in menstruating endurance athletes and distinguish it from improvement in exercise function. Population, treatment, assessment interval, laboratory outcome, exercise outcome and follow-up completeness were examined. A retrospective cohort of 22 female athletes documented considerable variation in ferritin decline after intravenous iron. IRONWOMAN randomised 26 recreationally active women and identified better running economy at four weeks, without between-group differences in peak oxygen uptake, lactate threshold or haemoglobin mass; its three-month blood assessments followed unblinding and an offer of iron to placebo participants. In 150 iron-depleted women, daily and alternate-day oral treatment produced end-of-course ferritin medians of 43.8 and 44.8 μg/L, respectively, after different treatment durations. In a separate bleeding-treatment trial of 165 women, six-cycle ferritin medians increased from 19 to 34 μg/L with a levonorgestrel-releasing intrauterine system and from 19 to 21 μg/L with cyclic medroxyprogesterone acetate. End-of-course ferritin, ferritin during continued supplementation and ferritin after treatment cessation describe different treatment conditions. Athlete trials support selected short-term functional benefits, while bleeding-treatment trials demonstrate improvements in iron indices in non-athlete populations. These findings do not establish a reduction in recurrent iron deficiency among endurance athletes through a particular bleeding-treatment regimen.